Group 1 - The stock price of Zhaoyan New Drug (603127) reached a new high of 19.49 HKD, surpassing the previous high in March and marking the highest price since September 2023 [1] - The stock experienced significant volatility, with a nearly 30% drop in April due to market turbulence and regulatory changes, followed by a recovery of over 40% in May [1][4] - After peaking on June 17, the stock faced a three-day decline, dropping to a low of 13.89 HKD, a decrease of 28.73% from the peak [1] Group 2 - The Hang Seng Healthcare Index also rebounded after a five-day decline, indicating continued upward momentum in the Hong Kong pharmaceutical sector [2] - Investors are closely watching whether Zhaoyan New Drug can achieve new highs amid ongoing market fluctuations [2] Group 3 - Since the beginning of the year, southbound funds have accumulated a net purchase of nearly 700 billion HKD in Hong Kong stocks, with the healthcare sector showing significant gains [4] - The holding ratio of southbound funds in Zhaoyan New Drug increased from 37.58% to 40.64% in 2025, indicating a trend of increased investment [4][6] - The investment behavior of northbound funds shifted from "buying on dips" to "buying on rises" and back to "buying on dips" again, reflecting changing market dynamics [6] Group 4 - The recent surge in the Hong Kong innovative drug sector is driven by improved performance, policy optimization, and low valuations [4] - The financing environment for the domestic biopharmaceutical sector has improved, with a notable increase in investment cases and amounts in Q1 2025 [7] - The number of clinical approvals for new drugs in China has significantly increased, with 186 first-class new drugs receiving clinical approval in Q1 2025 [8][10] Group 5 - Zhaoyan New Drug reported a 115.11% year-on-year increase in net profit for Q1 2025, indicating strong financial performance despite market fluctuations [10] - The National Medical Products Administration's recent announcement aims to optimize the clinical trial review process, potentially accelerating the approval timeline for innovative drugs [10][12] - The average duration for new drug IND tasks in China is currently 71 days, with plans to reduce this to 30 working days, which could stimulate demand for Zhaoyan New Drug's services [12]

Core Viewpoint - The company, Zhaoyan New Drug, has experienced a decline in stock price and revenue, while showing significant growth in net profit, indicating mixed performance in the current market environment [1]. Company Summary - Zhaoyan New Drug's closing stock price on July 2 was 21.95 yuan, down 1.57%, with a rolling PE ratio of 42.46 times and a total market capitalization of 16.451 billion yuan [1]. - The company operates primarily in non-clinical safety evaluation services for drugs, clinical research services, and sales of experimental animals and related products [1]. - For the first quarter of 2025, Zhaoyan New Drug reported revenue of 287 million yuan, a year-on-year decrease of 11.54%, while net profit reached 41.1195 million yuan, reflecting a year-on-year increase of 115.11%, with a gross profit margin of 28.61% [1]. Industry Summary - The average PE ratio for the medical services industry is 41.66 times, with a median of 43.69 times, placing Zhaoyan New Drug at the 29th position within the industry [1]. - As of the first quarter of 2025, 22 institutions held shares in Zhaoyan New Drug, including 20 funds, with a total holding of 72.9482 million shares valued at 1.484 billion yuan [1]. - The industry comparison shows that Zhaoyan New Drug's PE ratio is higher than the industry average but lower than the median, indicating a competitive yet challenging market position [2].

主力合约前20席位中，多头增仓前三名分别是：中信期货、持仓9862、增仓2105，方正中期、持仓6164、增仓1321，国泰君安、 持仓12113、增仓1311；多头减仓前三名分别是：华泰期货、持仓3793、减仓-3836，银河期货、持仓6399、减仓-722，永安期货、 持仓4129、减仓-717； 新浪期货 根据交易所数据，截至7月02日收盘主力合约烧碱2509,涨跌+3.19%,成交量61.08万手，持仓数据显示前20席位呈现净 空，差额头寸为12406手。 烧碱期货全合约总计成交72.88万手，比上一日新增3.37万手。全合约前20席位多头持仓15.94万手，比上一日减少1223手。全合约 前20席位空头持仓17.13万手，比上一日减少4793手。 根据合并数据显示，多头前三席位为国泰君安，总持仓21925、东证期货，总持仓13301、中信期货，总持仓12318；空头前三席位 为国泰君安，总持仓24831、东证期货，总持仓15984、华泰期货，总持仓11711； | | 名次 会员名称 成交量(双边) | | 壇減 | 会员 | 持买单 | 增减 | 会员 | 持卖单 | 增减 | | --- | - ...

Overview of Investment Fund Collaboration - The company, Beijing Zhaoyan New Drug Research Center Co., Ltd., has approved an investment of up to 20 million RMB to participate in the establishment of the Huaxia Zhiyuan Venture Capital Fund [2][3] - The fund aims to engage in investment activities primarily in unlisted companies within the full industry chain of molecular diagnostics and targeted therapies [4][5] Partnership Agreement Details - A partnership agreement has been signed with Huaxia Equity Investment Fund Management (Beijing) Co., Ltd., which will act as the general partner and fund manager [2][4] - The partnership has a term of 20 years, with an investment operation period of 7 years, extendable by up to 2 years under certain conditions [3][4] Fund Structure and Financials - The target total subscription amount for the fund is 35 million RMB, with a minimum contribution of 10 million RMB for each limited partner [3][5] - The management fee is set at 1% per year of the total paid-in capital, calculated daily [5] Investment Focus - The fund will focus on investments in the full industry chain of biomedicine for molecular diagnostics and targeted therapies, particularly in the development of Alpha-targeted therapies [4][5]

证券简称：昭衍新药 证券代码：603127 公告编号：2025-026 北京昭衍新药研究中心股份有限公司 关于与专业投资机构合作参与投资设立基金 的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、与专业投资机构合作参与投资设立产业基金情况概述 北京昭衍新药研究中心股份有限公司（以下简称"昭衍新药"、"公司"）于 2024 年 12 月 20 日召开第四届董事会第十一次会议，审议通过了《关于公司与专业投 资机构合作参与投资设立基金的议案》，同意公司或指定子公司以不超过 2,000 万人民币投资参与华夏致远创业投资基金（北京）合伙企业（有限合伙）（暂定 名）（以下简称"本基金"、"合伙企业"）的发起设立。华夏股权投资基金管 理（北京）有限公司为本基金的普通合伙人、执行事务合伙人，并担任本基金的 基金管理人。具体内容详见公司于 2024 年 12 月 21 日在上海证券交易所网站 （www.sse.com.cn）及指定信息披露媒体《上海证券报》披露的《昭衍新药关于 与专业投资机构合作参与投资设立基金的公告》（公告编号： ...

Core Insights - The National Healthcare Security Administration and the National Health Commission issued measures to support the high-quality development of innovative drugs, focusing on the entire chain from research and development to payment systems [1] - The inclusion of innovative drug directories in commercial health insurance is expected to enhance the multi-tiered medical security system and provide economic support for the development of innovative drugs [1][2] - The stock market reacted positively, with significant gains in innovative drug concept stocks and ETFs, indicating strong investor interest and liquidity in this sector [1][2] Industry Developments - The establishment of a commercial insurance innovative drug directory marks a significant step in enhancing the role of commercial insurance in the multi-tiered medical security system, providing payment support for high-priced innovative drugs and medical devices [2] - The "18A" policy has catalyzed a wave of medical companies listing in Hong Kong, focusing on cutting-edge medical industry directions, which has attracted market attention and investment [2] Market Performance - The Hong Kong innovative drug ETF (513120) saw a rise of over 2%, with a trading volume of 4.1 billion yuan, leading the market in the pharmaceutical ETF category [1] - The latest scale of the Hong Kong innovative drug ETF reached 13.4 billion yuan, indicating its leading position in the market [1] - The innovative drug ETF (515120) also performed well, with a trading volume of 145 million yuan and a net inflow of nearly 200 million yuan over five consecutive days [1]

Core Viewpoint - The A-share pharmaceutical sector experienced a significant rally, with notable stocks such as Saily Medical hitting the daily limit, Rongchang Bio rising over 7%, and Shutai Shen increasing by more than 6% due to supportive government measures for innovative drug development [1] Group 1 - The National Healthcare Security Administration and the National Health Commission issued measures to support the high-quality development of innovative drugs [1] - The new measures include the use of medical insurance data to facilitate the research and development of innovative drugs [1]

Market Overview - The Shanghai Composite Index closed at 3444.43 points, above the five-day moving average, with a gain of 0.59% [1] - The total trading volume of A-shares reached 1,517.37 billion yuan [1] Stocks Performance - A total of 664 A-shares have surpassed the five-day moving average, indicating positive momentum [1] - Notable stocks with significant deviation rates include: - Morningstar Airlines (15.14%) - Xiangyu Medical (14.86%) - Qifeng Precision (13.27%) [1][2] - Stocks with smaller deviation rates that just crossed the five-day moving average include: - China Duty Free Group - Shanghai Yizhong - Shanjin International [1] Top Stocks by Deviation Rate - The following stocks had the highest deviation rates from the five-day moving average: - Morningstar Airlines: 19.99% increase, 15.14% deviation [2] - Xiangyu Medical: 20.01% increase, 14.86% deviation [2] - Qifeng Precision: 17.25% increase, 13.27% deviation [2] - Other notable stocks include: - Lianjian Optoelectronics: 19.92% increase, 10.74% deviation [2] - Songsheng Co.: 13.73% increase, 10.55% deviation [2]

Group 1 - The CSI Medical Index (399989) has shown a strong increase of 1.17%, with significant gains in constituent stocks such as Zhaoyan New Drug (603127) reaching a 10% limit up, and Kylin Pharmaceutical (002821) rising by 5.71% [1] - The leading medical ETF (560260) has experienced a 1.60% increase, with a trading volume of 16.8873 million yuan and an average daily trading volume of 14.2868 million yuan over the past year [1] - The leading medical ETF has achieved a net value increase of 9.14% over the past year, with the highest monthly return since inception being 29.94% and an average monthly return of 8.25% [1] Group 2 - As of May 30, 2025, the top ten weighted stocks in the CSI Medical Index account for 55.09%, with notable companies including WuXi AppTec (603259) and Mindray Medical (300760) [2] - The medical outsourcing service sector is expected to see a rebound, driven by its core position in the industry chain, valuation advantages, and signs of recovery in market conditions [2] - Despite the CRO industry facing challenges, the new listing policies on the Sci-Tech Innovation Board are anticipated to change market perceptions regarding the future development of the CRO sector [2]

Market Overview - The A-share market saw all three major indices rise in the morning session, with the Shanghai Composite Index up 0.2%, the Shenzhen Component Index up 0.54%, and the ChiNext Index up 0.93% [1] - The total market turnover reached 932.6 billion yuan, a decrease of 81.1 billion yuan compared to the previous day, with over 3,500 stocks rising [1] Sector Performance - The gaming, military, brain-computer interface, and photolithography concept stocks led the gains, while the banking, securities, and dairy sectors experienced declines [3] - Notable stocks in the military sector included Hengyu Xintong (300965), Chenxi Aviation (300581), and Zhongbing Hongjian (000519), all of which hit the daily limit [3] - The gaming sector saw significant increases with Kaiying Network (002517) and Giant Network (002558) both reaching the daily limit [3] - Photolithography concept stocks were active, with Blue Eagle Equipment (300293) hitting the daily limit, along with Kaimete Gas (002549) and Zhongci Electronics (003031) [3] - The innovative drug sector rebounded, with Zhaoyan New Drug (603127) also hitting the daily limit [3] - The banking and securities sectors faced early declines, with Guosheng Jinkong (002670) dropping over 5% [3] Hot Stocks - The strongest sectors included new energy vehicles, military, and specialized innovative companies, with multiple stocks hitting daily limits [8][9][10] - In the new energy vehicle sector, 16 stocks reached the daily limit, with the highest consecutive limit being 9 days [8] - The military sector had 14 stocks hitting the daily limit, with the highest consecutive limit also being 9 days [9] - The specialized innovative sector had 13 stocks hitting the daily limit, with a maximum of 3 consecutive limits [10] Sector Insights - The military equipment sector is expected to benefit from increasing global military trade demand and domestic military modernization efforts, potentially leading to a dual boost in fundamentals and industry valuations [12] - The gaming sector is supported by a record number of game approvals, indicating regulatory support for healthy industry development [13] - The brain-computer interface sector is gaining attention due to advancements from Neuralink, with significant usage data reported from trial participants [14] - The digital currency sector is poised for growth as Hong Kong aims to enhance cross-border payment efficiency through stablecoins, with new regulations set to take effect [15]